MOSAIC TRIAL

J Clin Oncol. 2009 May 18. [Epub ahead of print]

Related Articles, LinkOut

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial.

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A.

Hôpital Pitié-Salpêtrière; Université Paris 06; Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) Oncology Multidisciplinary Group; Hôpital Saint-Antoine and L'Institut National de la Santé et de la Recherche Médicale, Paris, France; Arcispedale Santa Maria Nuova, Reggio Emilia; Ospedale Mater Salutis, Legnago, Italy; Institut Català d'Oncologia, l'Hospitalet de Llobregat, Llobregat; Valle d'Hebron University Hospital, Barcelona; Hospital Marqués de Valdecilla, Santander, Spain; Dorset Cancer Centre, Royal Bournemouth Hospital, Bournemouth; Royal Surrey County Hospital, Guildford, Surrey; North Middlesex Hospital, London, United Kingdom; and Southern Medical Day Care Centre, Wollongong, Australia.

PURPOSE: Three-year disease-free survival (DFS) was significantly improved in patients who had undergone resection with curative intent for stage II or III colon cancer who received bolus plus continuous-infusion fluorouracil plus leucovorin (LV5FU2) with the addition of oxaliplatin (FOLFOX4). Final results of the study, including 6-year overall survival (OS) and 5-year updated DFS, are reported. PATIENTS AND METHODS: A total of 2,246 patients were randomly assigned to receive LV5FU2 or FOLFOX4 for 6 months. The primary end point was DFS. Secondary end points were OS and safety. RESULTS: Five-year DFS rates were 73.3% and 67.4% in the FOLFOX4 and LV5FU2 groups, respectively (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.93; P = .003). Six-year OS rates were 78.5% and 76.0% in the FOLFOX4 and LV5FU2 groups, respectively (HR = 0.84; 95% CI, 0.71 to 1.00; P = .046); corresponding 6-year OS rates for patients with stage III disease were 72.9% and 68.7%, respectively (HR = 0.80; 95% CI, 0.65 to 0.97; P = .023). No difference in OS was seen in the stage II population. The incidence of second noncolorectal cancers was 5.5% and 6.1% in the FOLFOX4 and LV5FU2 groups, respectively. Among patients receiving oxaliplatin, the frequency of grade 3 peripheral sensory neuropathy was 1.3% 12 months after treatment and 0.7% at 48 months. CONCLUSION: Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease.